Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 24 April 2019, 08:36 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected as Competitive ICT Strategy Company for 2019
Recognized for Taking on Challenge of Transformation to New Business Models by Integrating Management and Ict Strategies

TOKYO, Apr 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Competitive IT Strategy Company 2019 as a company that is engaged in the strategic utilization of IT. This marks the first time a pharmaceutical company has been selected as a Competitive IT Strategy Company.

The aim of the Competitive IT Strategy Company program is to introduce companies as attractive companies to investors who emphasize improving corporate value over the mid- to long-term and to promote companies? Competitive IT Strategies. Under the program, METI and TSE jointly select and announce companies who are engaged in the strategic use of IT.

Companies are assessed according to five areas: "Utilization of IT to increase corporate value in terms of management policies and plans," "Strategic utilization of IT to increase corporate value," "Systems and personnel for promoting the Competitive IT Strategy," "Fundamental initiatives supporting the Competitive IT Strategy," as well as "Initiatives focused on evaluating and improving IT investment to increase corporate value."

In this fifth iteration of the program, 29 companies were selected from among approximately 3,600 publicly-listed Japanese companies.

Under the ICT Driven Innovation strategy in the medium-term business plan EWAY2025, Eisai is promoting various initiatives using IT for the enhancement of corporate value in order to realize a digital transformation that integrates management and ICT strategies. Eisai?s recognition as a Competitive IT Strategy Company highlighted its utilization of IT to contribute to the enhancement of corporate value as well as its application of new digital technologies.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will take this opportunity to continue employing competitive IT strategy to further improve productivity and create innovation, and strive to further enhance corporate value.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120 


Apr 24, 2019 08:36 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
May 17, 2019 15:34 HKT/SGT
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 16, 2019 07:37 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 10, 2019 12:34 HKT/SGT
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10, 2019 11:55 HKT/SGT
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 9, 2019 11:33 HKT/SGT
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 9, 2019 11:06 HKT/SGT
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 8, 2019 08:37 HKT/SGT
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
May 1, 2019 08:09 HKT/SGT
Eisai Buys Out Purdue Rights to End Collaboration
Apr 24, 2019 16:53 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
Apr 8, 2019 13:06 HKT/SGT
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: